Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:GEMP NASDAQ:KMDA NASDAQ:MCRB NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$7.71+2.8%$8.03$6.10▼$28.67$534.54M1.41395,256 shs72,401 shsGEMPGemphire Therapeutics$0.64+2.7%$4.97$0.24▼$1.49$9.50M2.82127,174 shs79,747 shsKMDAKamada$7.80+1.4%$7.08$5.08▼$9.16$446.57M0.9695,788 shs14,310 shsMCRBSeres Therapeutics$12.17+4.9%$8.34$6.53▼$30.60$106.09M2.75132,297 shs60,866 shsOCULOcular Therapeutix$10.41+4.9%$8.26$5.79▼$11.78$1.65B1.431.42 million shs731,303 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics+4.60%+6.69%-12.28%+9.01%-62.93%GEMPGemphire Therapeutics-3.98%-3.28%-10.13%-54.42%-86.50%KMDAKamada-0.13%-0.77%+12.41%+27.69%+34.85%MCRBSeres Therapeutics+6.91%+8.41%+40.95%+8.21%-40.40%OCULOcular Therapeutix+3.23%+9.01%+9.98%+45.03%+48.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCYCBicycle Therapeutics3.8182 of 5 stars4.44.00.00.02.22.50.6GEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKMDAKamada4.044 of 5 stars3.33.00.00.02.01.73.8MCRBSeres Therapeutics3.5484 of 5 stars2.92.00.04.62.80.80.0OCULOcular Therapeutix3.9377 of 5 stars3.51.00.04.12.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.70Moderate Buy$25.00224.21% UpsideGEMPGemphire Therapeutics 0.00N/AN/AN/AKMDAKamada 2.67Moderate Buy$13.0066.58% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67505.31% UpsideOCULOcular Therapeutix 3.00Buy$17.3366.51% UpsideCurrent Analyst Ratings BreakdownLatest OCUL, BCYC, GEMP, KMDA, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.005/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.005/5/2025BCYCBicycle TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.005/2/2025BCYCBicycle TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.005/2/2025BCYCBicycle TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.005/2/2025BCYCBicycle TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.005/2/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/1/2025BCYCBicycle TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$35.28M15.14N/AN/A$11.48 per share0.67GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AKMDAKamada$160.95M2.79$0.50 per share15.68$4.51 per share1.73MCRBSeres TherapeuticsN/AN/AN/AN/A$1.61 per shareN/AOCULOcular Therapeutix$63.72M26.03N/AN/A$2.01 per share5.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)GEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AKMDAKamada$14.46M$0.2926.7824.390.939.60%6.31%4.43%8/13/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/6/2025 (Estimated)Latest OCUL, BCYC, GEMP, KMDA, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025OCULOcular Therapeutix-$0.35N/AN/AN/A$13.12 millionN/A8/5/2025Q2 2025BCYCBicycle Therapeutics-$0.95N/AN/AN/A$9.43 millionN/A5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/A5/1/2025Q1 2025BCYCBicycle Therapeutics-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A14.8614.86GEMPGemphire TherapeuticsN/A0.670.67KMDAKamadaN/A3.301.93MCRBSeres TherapeuticsN/A2.112.11OCULOcular Therapeutix0.2610.2210.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%GEMPGemphire Therapeutics17.53%KMDAKamada20.38%MCRBSeres Therapeutics59.34%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%GEMPGemphire Therapeutics22.70%KMDAKamada36.10%MCRBSeres Therapeutics4.70%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.25 million63.37 millionOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableKMDAKamada36057.51 million36.75 millionOptionableMCRBSeres Therapeutics3308.73 million8.32 millionOptionableOCULOcular Therapeutix230159.30 million155.64 millionOptionableOCUL, BCYC, GEMP, KMDA, and MCRB HeadlinesRecent News About These CompaniesOcular Therapeutix (NASDAQ:OCUL) Shares Up 5.5% - Here's What HappenedJuly 8 at 12:39 PM | marketbeat.com847,468 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Peregrine Capital Management LLCJuly 1, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Up 7.7% - What's Next?June 30, 2025 | marketbeat.comOcular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - NasdaqJune 27, 2025 | nasdaq.comOcular Therapeutix sharpens focus with retina-centric rebrandJune 27, 2025 | fiercepharma.comFOcular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused CompanyJune 26, 2025 | finance.yahoo.comOcular Therapeutixâ„¢ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused CompanyJune 26, 2025 | globenewswire.comOcular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?June 25, 2025 | zacks.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up - Here's WhyJune 24, 2025 | marketbeat.comDeltec Asset Management LLC Has $19.91 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 21, 2025 | marketbeat.comOcular Therapeutix to present at Clinical Trials at the Summit 2025June 18, 2025 | ophthalmologytimes.comOOcular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three yearsJune 17, 2025 | uk.finance.yahoo.comAssenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 17, 2025 | marketbeat.comOcular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025June 16, 2025 | globenewswire.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from BrokeragesJune 15, 2025 | marketbeat.comQ&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trialJune 11, 2025 | ophthalmologytimes.comOCourier Capital LLC Boosts Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 10, 2025 | marketbeat.comOcular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMDJune 2, 2025 | ophthalmologytimes.comOH.C. Wainwright maintains $15 target on Ocular Therapeutix stockMay 31, 2025 | investing.comDemystifying Ocular Therapeutix: Insights From 7 Analyst ReviewsMay 29, 2025 | benzinga.comOcular Therapeutix chief scientific officer sells $21,712 in stockMay 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCUL, BCYC, GEMP, KMDA, and MCRB Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$7.71 +0.21 (+2.81%) As of 11:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Gemphire Therapeutics NASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Kamada NASDAQ:KMDA$7.80 +0.10 (+1.35%) As of 11:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Seres Therapeutics NASDAQ:MCRB$12.17 +0.57 (+4.91%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Ocular Therapeutix NASDAQ:OCUL$10.41 +0.49 (+4.94%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
